Previous 10 | Next 10 |
--News Direct-- Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, ac...
2023-06-28 12:43:06 ET Atossa Therapeutics ( NASDAQ: ATOS ) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer therapy ( Z )-endoxifen reached 30%. A selective e...
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial PR Newswire SEATTLE and SAN FRANCISCO , June 28, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage ...
2023-06-27 09:23:14 ET Biopharmaceutical company Atossa Therapeutics ( NASDAQ: ATOS ) said on Tuesday that its board has approved an up to $10M share repurchase program. The share repurchase program will be implemented through Dec. 31. The size of the repurchase authoriza...
SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that its Board of Directors has...
2023-06-23 08:13:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The conventional definition of a penny stock is one that trades below $1. However, it’s more common to define a penny stock as any stock that trades for less than $5. These stocks carr...
SEATTLE, June 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces their role as a corporate spons...
--News Direct-- Atossa Therapeutics CEO Dr Steven Quay joined Steve Darling from Proactive to share news the company has been granted a new patent directed to enterically encapsulated endoxifen compositions formulated as a suspension by the United States Patent and Trademark Office. These...
SEATTLE, June 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the United States Patent a...
SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that Chief Executive Officer St...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s ...